Drug research

ALKS 2680

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic HypersomniaNCT06843590	Alkermes, Inc.	Phase 2	Active not recruiting	2026-11Estimated
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)NCT06358950	Alkermes, Inc.	Phase 2	Completed	2025-06-19Actual
A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2NCT06555783	Alkermes, Inc.	Phase 2	Completed	2025-11-11Actual

Alkermes, Inc.Active not recruitingPrimary completion: 2026-11 · Estimated

Trial details

Alkermes, Inc.CompletedPrimary completion: 2025-06-19 · Actual

Trial details

Alkermes, Inc.CompletedPrimary completion: 2025-11-11 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.